|
Home /
Janssen-Cilag
Janssen-Cilag Pharmaceutical
 Janssen-Cilag
Pharmaceutical
Janssen-Cilag is a world leading
research-based pharmaceutical company and has over 6,000 employees throughout
Europe, involved with the marketing and development of medicines and with a
focus on such therapeutic areas as pain, psychiatry, neurology,
gastrointestinal and fungal diseases
Cilag was founded in Switzerland in
1936, with Janssen Pharmaceutica being established in 1953 by Dr Paul Janssen,
who has been described as "arguably the most successful drug discoverer of all
time", being responsible for several breakthrough drugs in areas such as
anaesthesia, pain management, psychiatry, gastroenterology, mycology and
numerous other therapeutic areas.
In 1959, Cilag joined the Johnson
& Johnson family of companies, followed by anssen Pharmaceutica in 1961.
This initiated an international expansion that has resulted in the
establishment of Janssen Pharmaceutica companies in virtually all countries of
the world.
In 1994, Janssen Pharmaceutica integrated its sales and
marketing organisations worldwide with that of Cilag and became Janssen-Cilag.
Later the two research organisations merged into Johnson & Johnson
Pharmaceutical Research & Development (J&JPRD) and Tibotec was created
in 1994 by a group of scientists wanting to discover and develop innovative
HIV/AIDS drugs and superior anti-infectives.
Janssen-Cilag pharmaceutical products
Pain management / anaesthetics:
RAPIFEN®, SUFENTA®, FENTANYL® and
DUROGESIC®.
Psychiatry: HALDOL®, RISPERDAL®, RISPERDAL®
CONSTA and CONCERTA®.
Neurology: TOPAMAX® and
REMINYL®.
Gastrointestinal disease: MOTILIUM® and
PARIET®.
Fungal disease: DAKTARIN®, NIZORAL® and
SPORANOX®.
Ortho Biotech
Ortho Biotech is a division of
Janssen-Cilag and is involved with the development / marketing of biochemical
medicines.
Ortho Biotech Inc. was established by Johnson & Johnson
in the United States in 1990 and has been a market leader in the treatment of
anaemia across multiple therapeutic categories for more than 15 years.
Latest Janssen-Cilag pharmaceutical news
New Antibiotic To Treat Serious Infections. Invega® receives marketing authorisation in European Union for threatment of schizophrenia.. Janssen-Cilag International NV submits marketing authorization application in Europe for new antiobiotic.. INVEGA® receives positive opinion from European Committee for Human Medicinal Products (CHMP). INVEGA™ approved by FDA as new treatment for schizophrenia. Mother & daughters' journey through madness. European Headache Alliance launches at European Parliament with 1st ever Migraine Day of Action. Study shows Topamax® reduces number of monthly migraine days in chronic migraine patients. read more
Janssen-Cilag further information:
www.janssen-cilag.co.uk/ /
www.janssen-cilag.com/ /
Janssen-Cilag news
Page last updated:
11/06/08 |
